ABT-199

DRUG12 trials

Sponsors

AbbVie, AbbVie (prior sponsor, Abbott), German CLL Study Group, Peter MacCallum Cancer Centre, Australia

Conditions

AMLAcute Myelogenous LeukemiaAcute Myeloid LeukemiaChronic Lymphocytic LeucemiaChronic Lymphocytic LeukemiaLupus ErythematosusMantle Cell LymphomaMyelogenous Leukemia

Phase 1

A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma

CompletedNCT01328626

AbbVieChronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma

Start: 2011-05-23End: 2020-05-08Updated: 2022-02-23

A Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Combination With Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma

CompletedNCT01594229

AbbVieNon-Hodgkin's Lymphoma

Start: 2012-05-21End: 2020-07-14Updated: 2021-08-02

A Phase 1b Study Evaluating the Safety and Tolerability of ABT-199 in Combination With Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

CompletedNCT01682616

AbbVieChronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

Start: 2012-07-25End: 2022-06-23Updated: 2023-06-06

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-199 in Female Patients With Systemic Lupus Erythematosus (SLE)

CompletedNCT01686555

AbbVie (prior sponsor, Abbott)Lupus Erythematosus

Start: 2012-11-30End: 2015-06-30Updated: 2017-11-20

A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy

CompletedNCT01794507

AbbVieRelapsed/Refractory Multiple Myeloma

Start: 2012-11-19End: 2019-07-16Updated: 2021-08-02

A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-199

CompletedNCT01969669

AbbVieNon-Hodgkin's Lymphoma

Start: 2013-12-31End: 2014-09-30Updated: 2017-11-20

An Extension Study of ABT-199 in Subjects With Advanced Non-Hodgkin's Lymphoma

CompletedNCT01969695

AbbVieNon-Hodgkin's Lymphoma

Start: 2013-12-20End: 2019-12-16Updated: 2019-12-19

A Study to Assess the Effect of Rifampin on the Metabolism of ABT-199

WithdrawnNCT01969682

AbbVieNon-Hodgkin's Lymphoma

Start: 2014-04-30End: 2014-05-31Updated: 2014-05-26

Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML)

TerminatedNCT02203773

AbbVieAcute Myelogenous Leukemia, Myelogenous Leukemia, Treatment Naive AML

Start: 2014-10-06End: 2022-06-16Updated: 2023-05-16

Phase 2

A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML)

CompletedNCT01994837

AbbVieAcute Myelogenous Leukemia, Acute Myeloid Leukemia, AML

Start: 2013-11-30End: 2014-12-31Updated: 2018-06-06

Sequential Regimen of Bendamustine-Debulking Followed by ABT-199 and GA101-Induction and -Maintenance in CLL (CLL2-BAG)

CompletedNCT02401503

German CLL Study GroupChronic Lymphocytic Leucemia

Start: 2015-05-06End: 2024-12-17Updated: 2025-06-10

ABT-199 & Ibrutinib in Mantle Cell Lymphoma (AIM)

Peter MacCallum Cancer Centre, AustraliaMantle Cell Lymphoma

Start: 2015-07-22End: 2025-06-30Updated: 2023-08-21

Related Papers

Venetoclax and ibrutinib induces durable clinical responses in marginal zone lymphoma.

2025-12-11

Outcomes of patients treated with venetoclax plus azacitidine versus azacitidine alone stratified by advanced age and acute myeloid leukemia composite model

Leukemia2025-09-051 citations

Marginal Zone Lymphoma Is Associated with Dysregulated Peripheral Blood Immunity Which Is Not Changed By Ibrutinib-Venetoclax Treatment

Blood2024-11-05

Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine

Blood2024-08-12102 citations

Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions

Blood2024-04-2515 citations

Reassessing the chronic lymphocytic leukemia International Prognostic Index in the era of targeted therapies

Blood2024-04-1525 citations

Relationship Between Venetoclax Exposure and Undetectable Minimal Residual Disease Rates in Relapsed/Refractory Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of Six Clinical Studies

HemaSphere2023-11-17

Real World Outcome of Unfit Patients with Acute Myeloid Leukemia Treated with the Combination Venetoclax Plus Hypomethylating Agents in the Gimema AML2320 Observational Trial

Blood2023-11-026 citations

Outcomes in Chemotherapy-Ineligible Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia Treated with Venetoclax Plus Azacitidine: A Pooled Analysis

Blood2023-11-024 citations

Treatment Outcomes of Stem Cell Transplant in Patients with Acute Myeloid Leukemia Treated with Venetoclax in Combination with Hypomethylating Agents: Experience from Routine Clinical Practices in the United States

Blood2023-11-021 citations

Real-World Outcomes with Intensive Chemotherapy in Acute Myeloid Leukemia Patients Deemed “Unfit” for Remission Induction By Landmark Trials' Criteria

Blood2023-11-02

P525: LONG-TERM OUTCOMES OF STEM CELL TRANSPLANT IN OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH VENETOCLAX + HMA THERAPIES

HemaSphere2023-08-018 citations

P521: FINDINGS FROM AN ANALYSIS OF PATIENTS WITH MONOCYTIC AND MONOCYTIC-LIKE ACUTE MYELOID LEUKEMIA (AML), INCLUDING AML-M4 AND AML-M5, TREATED WITH VENETOCLAX (VEN) PLUS AZACITIDINE (AZA)

HemaSphere2023-08-014 citations

P418: DELE1 LOSS AND DYSFUNCTIONAL INTEGRATED STRESS SIGNALING IN TP53 MUTATED AML IS A NOVEL PATHWAY FOR VENETOCLAX RESISTANCE

HemaSphere2023-08-01

Abstract 2530: DELE1 loss and dysfunctional integrated stress signaling in <i>TP53</i> mutated AML is a novel pathway for venetoclax resistance

Cancer Research2023-04-042 citations

ELN Risk Stratification Is Not Predictive of Outcomes for Treatment-Naïve Patients with Acute Myeloid Leukemia Treated with Venetoclax and Azacitidine

Blood2022-11-1583 citations

Real-World Treatment Experience of Venetoclax in Combination with Hypomethylating Agents in Patients with Newly Diagnosed Acute Myeloid Leukemia: Updated Experience from a Predominately Community Setting in the US

Blood2022-11-151 citations

Outcomes in Patients with Poor-Risk Cytogenetics with or without <i>TP53</i> Mutations Treated with Venetoclax and Azacitidine

Clinical Cancer Research2022-08-25136 citations

Bioavailability Evaluation of Venetoclax Lower-Strength Tablets and Oral Powder Formulations to Establish Interchangeability with the 100 mg Tablet.

2022-07-137 citations

Impact of <i>F</i> <i>LT3</i> Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia

Clinical Cancer Research2022-01-2181 citations

73 more papers not shown